Charles Schwab Investment Management Inc Crispr Therapeutics Ag Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 933,204 shares of CRSP stock, worth $67.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

933,204

Previous 713,539 30.79%

Holding current value

$67.5 Million

Previous $24.3 Million 86.94%

% of portfolio

0.01%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$31.27 - $48.64 $6.87 Million - $10.7 Million	219,665 Added 30.79%	933,204 $45.4 Million
Q1 2025 Sep 15, 2025	SELL	$34.03 - $53.02 $7.48 Million - $11.6 Million	-219,665 Reduced 23.54%	713,539 $24.3 Million
Q1 2025 May 09, 2025	SELL	$34.03 - $53.02 $323,046 - $503,318	-9,493 Reduced 1.31%	713,539 $24.3 Million
Q4 2024 Feb 06, 2025	SELL	$38.65 - $55.15 $46,727 - $66,676	-1,209 Reduced 0.17%	723,032 $28.5 Million
Q3 2024 Nov 12, 2024	BUY	$44.62 - $62.75 $296,053 - $416,346	6,635 Added 0.92%	724,241 $34 Million
Q2 2024 Aug 12, 2024	BUY	$51.17 - $68.18 $2.48 Million - $3.3 Million	48,414 Added 7.23%	717,606 $38.8 Million
Q1 2024 May 08, 2024	BUY	$60.67 - $89.12 $980,973 - $1.44 Million	16,169 Added 2.48%	669,192 $45.6 Million
Q4 2023 Feb 06, 2024	BUY	$38.62 - $72.18 $582,582 - $1.09 Million	15,085 Added 2.36%	653,023 $40.9 Million
Q3 2023 Nov 08, 2023	SELL	$45.39 - $59.0 $398,206 - $517,607	-8,773 Reduced 1.36%	637,938 $29 Million
Q2 2023 Aug 09, 2023	BUY	$43.47 - $67.77 $257,950 - $402,147	5,934 Added 0.93%	646,711 $36.3 Million
Q1 2023 May 11, 2023	SELL	$41.0 - $56.12 $12,997 - $17,790	-317 Reduced 0.05%	640,777 $29 Million
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $743,669 - $1.25 Million	18,976 Added 3.05%	641,094 $26.1 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $16.7 Million - $23 Million	273,995 Added 78.71%	622,118 $40.7 Million
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $288,776 - $493,184	-6,680 Reduced 1.88%	348,123 $21.2 Million
Q1 2022 May 13, 2022	BUY	$53.19 - $79.24 $18.9 Million - $28.1 Million	354,803 New	354,803 $22.3 Million

Others Institutions Holding CRSP

# of Institutions

543

Shares Held

68.7M

Call Options Held

3.67M

Put Options Held

2.25M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $5.64B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Crispr Therapeutics Ag Transaction History